Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Finn

Showing results (311-320 of 527) with videos related to

Pageof 53
Sort By:
Nature Reviews. Disease Primers|February 12, 2024
Author Correction: Hepatocellular carcinomaJosep M Llovet, Robin Kate Kelley, Augusto Villanueva, et al.
Cancers|September 28, 2023
Indirect Treatment Comparison of First-Line CDK4/6-Inhibitors in Post-Menopausal Patients with HR+/HER2- Metastatic Breast CancerJoseph J Zhao, Khi Yung Fong, Yiong Huak Chan, et al.
Current Medical Research and Opinion|February 20, 2016
Impact of palbociclib plus letrozole on pain severity and pain interference with daily activities in patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer as first-line treatmentT Bell, J P Crown, I Lang, et al.
Liver Cancer|October 30, 2023
Albumin-Bilirubin Grade Analyses of Atezolizumab plus Bevacizumab versus Sorafenib in Patients with Unresectable Hepatocellular Carcinoma: A Post Hoc Analysis of the Phase III IMbrave150 StudyMasatoshi Kudo, Richard S Finn, Ann-Lii Cheng, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|March 20, 2021
Ramucirumab in patients with advanced hepatocellular carcinoma and elevated α-fetoprotein: Outcomes by treatment-emergent ascitesMasatoshi Kudo, Masafumi Ikeda, Peter R Galle, et al.
Breast Cancer Research : BCR|March 25, 2021
Comparative effectiveness of first-line palbociclib plus letrozole versus letrozole alone for HR+/HER2- metastatic breast cancer in US real-world clinical practiceAngela DeMichele, Massimo Cristofanilli, Adam Brufsky, et al.
International Journal of Molecular Sciences|February 5, 2013
Amplification Target ADRM1: Role as an Oncogene and Therapeutic Target for Ovarian CancerMarlena S Fejzo, Lee Anderson, Erika M von Euw, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 25, 2010
Lapatinib, a dual EGFR and HER2 kinase inhibitor, selectively inhibits HER2-amplified human gastric cancer cells and is synergistic with trastuzumab in vitro and in vivoZev A Wainberg, Adrian Anghel, Amrita J Desai, et al.
Global Change Biology|July 23, 2020
Mountain stoneflies may tolerate warming streams: Evidence from organismal physiology and gene expressionScott Hotaling, Alisha A Shah, Kerry L McGowan, et al.
Breast Cancer Research : BCR|March 14, 2020
Hematologic adverse events following palbociclib dose reduction in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: pooled analysis from randomized phase 2 and 3 studiesJohannes Ettl, Seock-Ah Im, Jungsil Ro, et al.
Pageof 53

Showing results (311-320 of 527) with videos related to

Sort By:
Pageof 53
Nature Reviews. Disease Primers|February 12, 2024
Author Correction: Hepatocellular carcinomaJosep M Llovet, Robin Kate Kelley, Augusto Villanueva, et al.
Cancers|September 28, 2023
Indirect Treatment Comparison of First-Line CDK4/6-Inhibitors in Post-Menopausal Patients with HR+/HER2- Metastatic Breast CancerJoseph J Zhao, Khi Yung Fong, Yiong Huak Chan, et al.
Current Medical Research and Opinion|February 20, 2016
Impact of palbociclib plus letrozole on pain severity and pain interference with daily activities in patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer as first-line treatmentT Bell, J P Crown, I Lang, et al.
Liver Cancer|October 30, 2023
Albumin-Bilirubin Grade Analyses of Atezolizumab plus Bevacizumab versus Sorafenib in Patients with Unresectable Hepatocellular Carcinoma: A Post Hoc Analysis of the Phase III IMbrave150 StudyMasatoshi Kudo, Richard S Finn, Ann-Lii Cheng, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|March 20, 2021
Ramucirumab in patients with advanced hepatocellular carcinoma and elevated α-fetoprotein: Outcomes by treatment-emergent ascitesMasatoshi Kudo, Masafumi Ikeda, Peter R Galle, et al.
Breast Cancer Research : BCR|March 25, 2021
Comparative effectiveness of first-line palbociclib plus letrozole versus letrozole alone for HR+/HER2- metastatic breast cancer in US real-world clinical practiceAngela DeMichele, Massimo Cristofanilli, Adam Brufsky, et al.
International Journal of Molecular Sciences|February 5, 2013
Amplification Target ADRM1: Role as an Oncogene and Therapeutic Target for Ovarian CancerMarlena S Fejzo, Lee Anderson, Erika M von Euw, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 25, 2010
Lapatinib, a dual EGFR and HER2 kinase inhibitor, selectively inhibits HER2-amplified human gastric cancer cells and is synergistic with trastuzumab in vitro and in vivoZev A Wainberg, Adrian Anghel, Amrita J Desai, et al.
Global Change Biology|July 23, 2020
Mountain stoneflies may tolerate warming streams: Evidence from organismal physiology and gene expressionScott Hotaling, Alisha A Shah, Kerry L McGowan, et al.
Breast Cancer Research : BCR|March 14, 2020
Hematologic adverse events following palbociclib dose reduction in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: pooled analysis from randomized phase 2 and 3 studiesJohannes Ettl, Seock-Ah Im, Jungsil Ro, et al.
Pageof 53